Clinical Trials Update from NCI, December 2022

National Cancer Institute banner

Having trouble viewing this email? View it as a Web page.

Bookmark and Share

Clinical Trials
Updates from the National Cancer Institute
Clinical Trials News
Atezolizumab attaching to PD-L1  

NCI Trial Leads to Atezolizumab Approval for Advanced Alveolar Soft Part Sarcoma

A clinical trial led by NCI has resulted in the first approved treatment for advanced alveolar soft part sarcoma (ASPS). The Food and Drug Administration (FDA) recently approved the immunotherapy drug atezolizumab (Tecentriq) for the treatment of adults and children 2 years and older with ASPS that has spread to other parts of the body or cannot be removed by surgery.

Illustration of brentuximab  

Brentuximab Approved for High-Risk Hodgkin Lymphoma in Children and Adolescents

Based on an NCI-sponsored clinical trial conducted by the Children’s Oncology Group, FDA has approved the drug brentuximab vedotin (Adcetris) in combination with chemotherapy for some children and adolescents with Hodgkin lymphoma.

Illustration of breast-conserving surgery  

Shorter Course of Radiation Is Effective and Safe for Some with Early-Stage Breast Cancer

In a large clinical trial, a condensed course of radiation therapy was as effective and safe as a longer standard course for those people with higher-risk early-stage breast cancer who had a lumpectomy to remove the tumor. This shorter radiation course makes treatment less of a burden for patients.

Image of the JNCI Monograph cover  

Monograph on Engaging Older Adults in Clinical Trials

A JNCI Monograph on "Engaging Older Adults in Cancer Clinical Trials Conducted in NCI’s Clinical Trials Network" is available now. The articles, developed through working groups formed for an NCI workshop held in April 2021, provide recommendations and new and innovative solutions to common accrual barriers.


NCI-Funded Canine Immunotherapy Clinical Trials Network

NCI’s Division of Cancer Treatment and Diagnosis recently announced a new comparative oncology research network, called PRECINCT 2022, to extend research in canine immunotherapy trials. Clinical trials for pet dogs with cancer provide valuable information for the development of future cancer treatments for people.

Clinical Trials Information for Patients and Caregivers

Clinical Trials Help Build the Future of Medicine

Clinical trials and the people who volunteer for them help improve our understanding of cancer. This page shares the stories of just a few of the thousands of people who have participated in cancer clinical trials conducted through NCI’s clinical trial programs and initiatives.


NCI's Clinical Trials Programs and Initiatives

This page describes NCI’s clinical trial programs and initiatives and explains how they help support a national infrastructure for clinical cancer research. These programs and initiatives help make cancer clinical trials more responsive to the rapid advances being made in cancer science.

Search for a clinical trial  

Find NCI-Supported Clinical Trials

Use our search form to find a clinical trial or other research study that may be right for you or a loved one.

NCI-Supported Clinical Trials That Are Recruiting Patients 

Comparing Immunotherapy Dosing Intervals for Advanced or Metastatic Cancer

This phase 1 trial will test an immune checkpoint inhibitor treatment, either nivolumab (Opdivo) or pembrolizumab (Keytruda), given at different dosing intervals for people with advanced or metastatic cancers. Doctors want to determine if giving the drugs with longer intervals between doses produces the same effect as giving them at the standard intervals.


Six-Drug Combination for Relapsed or Resistant B-Cell Lymphoma

This phase 1 trial will test a combination of six drugs for people with B-cell lymphoma that has either come back or not responded to treatment. Doctors want to see if these drugs are safe and effective when given together.


Evaluating Immune Responses after COVID Vaccination in Young People with Cancer

Vaccines work by bolstering the immune system to fight infection, but people with cancer often have suppressed or compromised immune systems. This study will examine how the immune systems of young people with cancer aged 6 months to 37 years respond to the COVID vaccine.